Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

SG Americas Securities LLC cut its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 28.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,518 shares of the company ...

Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ...

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

Healthcare is undergoing a seismic transformation. The old paradigm of brick-and-mortar hospitals is giving way to a new ...

The Africa Business Coalition for Health (ABCHealth) hosted a forum today at Medlab Middle East to discuss the AI solutions ...